# EDGAR Filing Document

**Accession Number:** 0002011674
**File Stem:** 0001213900-25-077096
**Filing Date:** 2025-8
**Character Count:** 3631
**Document Hash:** 64e5f9e208bf956c22f2770b9451949d
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001213900-25-077096.hdr.sgml**: 20250815

**ACCESSION NUMBER**: 0001213900-25-077096

**CONFORMED SUBMISSION TYPE**: 6-K

**PUBLIC DOCUMENT COUNT**: 1

**CONFORMED PERIOD OF REPORT**: 20250815

**FILED AS OF DATE**: 20250815

**DATE AS OF CHANGE**: 20250815

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** YD Bio Ltd
- **CENTRAL INDEX KEY:** 0002011674
- **STANDARD INDUSTRIAL CLASSIFICATION:** SERVICES-MEDICAL LABORATORIES [8071]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 000000000
- **STATE OF INCORPORATION:** E9
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 6-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 333-277076
- **FILM NUMBER:** 251222597

**BUSINESS ADDRESS:**
- **STREET 1:** 955 WEST JOHN CARPENTER FREEWAY
- **STREET 2:** SUITE 100-929
- **CITY:** IRVING
- **STATE:** TX
- **ZIP:** 75039
- **BUSINESS PHONE:** 619-500-7747

**MAIL ADDRESS:**
- **STREET 1:** 955 WEST JOHN CARPENTER FREEWAY
- **STREET 2:** SUITE 100-929
- **CITY:** IRVING
- **STATE:** TX
- **ZIP:** 75039

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** True Velocity, Inc./DE
- **DATE OF NAME CHANGE:** 20240209

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 6-K**

**REPORT OF FOREIGN PRIVATE ISSUER**

**PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE**

**SECURITIES EXCHANGE ACT OF 1934**

**For the month of August 2025**

**Commission File Number:** 

**<u>YD Bio Limited</u>**

**(Exact Name of Registrant as Specified in Charter)**

**12F., No. 3, Xingnan St.,<br> Nangang Dist.,<br> Taipei City 115001, Taiwan**

(Address of Principal Executive Offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F ☒ Form 40-F ☐

As previously disclosed in YD Bio Limited's (the "Company") Registration Statement on [Form F-4](https://www.sec.gov/Archives/edgar/data/2011674/000121390025007968/ea0218751-05.htm) initially filed with the Securities and Exchange Commission on January 30, 2025 and declared effective on July 18, 2025 (File No. 333-283428) (the "Registration Statement"), in connection with the closing of the business combination between the Company, Breeze Holdings Acquisition Corp., and YD Biopharma Limited described in the Registration Statement (the "Business Combination"), the Company received commitments of $13.2 million in connection with a PIPE financing to be completed concurrently with the closing of the Business Combination (the "PIPE Financing").

The subscribers to the PIPE Financing comprised four individuals, including Dr. Keng-Lian Ou, Ph.D. On August 13, 2025, the Company entered into a termination agreement releasing Dr. Ou from his subscription obligations and at the same time entered into a new subscription agreement with Ms. Hsiao Lan Wu. Ms. Lu's subscription is in the same amount and on the same terms as those previously agreed to by Dr. Ou. The Company continues to have commitments of $13.2 million in connection with the PIPE Financing following the substitution of Ms. Wu for Dr. Ou. Ms. Wu has no affiliation with the Company or any of its directors or officers.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

Date: August 15, 2025

---

| | |
|:---|:---|
| **YD Bio Limited** | **YD Bio Limited** |
| By: | /s/ J. Douglas Ramsey, Ph.D. |
| Name: | J. Douglas Ramsey, Ph.D. |
| Title: | Chief Executive Officer |

---